Deborah Berry
Payments from drug & device makers
Across 101 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$657
- Lilly USA, LLC$182
- Novo Nordisk$138
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$97
- GSK$88
- Nestle Healthcare Nutrition Inc.$46
- plus $263 from 12 others
What the payments were for
- Food & beverage$1,472100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $657 |
| Lilly USA, LLC | 14 | $182 |
| Novo Nordisk | 9 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| GSK | 6 | $88 |
| Nestle Healthcare Nutrition Inc. | 3 | $46 |
| Amarin Pharma, Inc. | 3 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Johnson & Johnson | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Abbott | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$1,472 in reported general payments places this provider in the 70th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 16 | $27,826 |
| JanuviaSitagliptin Phosphate | 22 | $22,867 |
| EliquisApixaban | 17 | $20,060 |
| JardianceEmpagliflozin | 17 | $18,159 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $13,497 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,094 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,041 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 122 | $2,741 |
| Estradiol | 25 | $2,357 |
| Ventolin HfaAlbuterol Sulfate | 29 | $1,992 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $1,780 |
| Atorvastatin Calcium | 170 | $1,742 |
| Metoprolol Succinate | 73 | $1,502 |
| Levothyroxine Sodium | 117 | $1,396 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $182 | $27,82616 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $22 | $23,20128 claims |
| PfizerEliquis | $16 | $20,06017 claims |
| GSKAnoro Ellipta | $88 | $13,49715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 755 medical providers in Michigan.
Other medical in Lenox
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.